See, that is a great point from this --- I hadn't yet thought about Samsung other affiliations being not so happy, etc.. Which ironically hits on me saying LL is either loved or hated by "pharma", so why not eliminate that unknown.

Yes sir, would need to grow with us & that's the beauty ---- would only be a 1 drug facility.

"Easy" approval process in comparison to typical.
"Easy" operational & lowest industry Cap-x due to what the facility supports -- stunning # of indications.

We'd have time to go this route --- while trials are proceeding. More approvals, simply expand as needed.

No "BP worries".

Just top of head brainstorm blabble & thanks for helping!